FDA-approved
Digestive & weight
Setmelanotide
Evidence
FDA approved
Class
Melanocortin 4 receptor agonist
KEY TAKEAWAY
Setmelanotide is a synthetic cyclic peptide that activates the melanocortin 4 receptor in the brain. It is sold as Imcivree. The FDA approved setmelanotide (Imcivree) in 2020 for obesity due to certain rare genetic disorders, and has expanded its use since.
Written by the Veylo editorial team · Updated
November 2026
What it is
Melanocortin 4 receptor agonist
Approved for
Obesity caused by specific rare genetic conditions, including Bardet-Biedl syndrome
Key fact
The FDA approved setmelanotide (Imcivree) in 2020 for obesity due to certain rare genetic disorders, and has expanded its use since.
Route
Daily subcutaneous injection
Evidence strength
FDA approved
Setmelanotide is a synthetic cyclic peptide that activates the melanocortin 4 receptor in the brain. It is sold as Imcivree.
It restores activity in the brain pathway that controls hunger and energy use when that pathway is impaired by certain rare genetic conditions.
The FDA approved setmelanotide (Imcivree) in 2020 for obesity due to certain rare genetic disorders, and has expanded its use since.
Obesity caused by specific rare genetic conditions, including Bardet-Biedl syndrome.
Skin darkening, injection-site reactions and nausea are reported. Depression and suicidal thoughts need monitoring.
U.S. FDA prescribing information for Setmelanotide. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.